Lonoctocog Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lonoctocog alfa: From Hemophilia A to Pseudo-von Willebrand Disease
One-Sentence Summary
Lonoctocog alfa (AFSTYLA) is a recombinant single-chain Factor VIII (rFVIII) product, approved internationally for the treatment and prophylaxis of bleeding episodes in patients with Hemophilia A. The TxGNN model predicts it may be effective for pseudo-von Willebrand disease, with a high algorithmic confidence score of 99.85%. However, there are currently 0 clinical trials and 0 publications supporting this repurposing direction, placing this prediction at the lowest evidence level (L5).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemophilia A (Factor VIII deficiency) — treatment and prophylaxis of bleeding |
| Predicted New Indication | Pseudo-von Willebrand disease (Platelet-type vWD) |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Lonoctocog alfa is a recombinant Factor VIII single-chain molecule (rFVIII-SC) that restores the function of the intrinsic coagulation pathway by forming a tenase complex with activated Factor IX (FIXa) on phosphatidylserine-rich platelet surfaces, thereby activating Factor X and propagating the coagulation cascade.
Pseudo-von Willebrand disease (platelet-type vWD) is caused by a gain-of-function mutation in platelet glycoprotein GPIbα, which results in enhanced affinity for ultra-large vWF multimers. This causes spontaneous binding and consumption of circulating large vWF multimers, secondarily depleting the carrier protein for Factor VIII and potentially shortening FVIII half-life. At the level of the knowledge graph, TxGNN likely scored this prediction highly because vWF and FVIII are tightly coupled nodes — vWF stabilises and chaperrones circulating FVIII in plasma.
However, the causal direction matters critically: the core defect in pseudo-vWD is in the platelet GPIb receptor, not in FVIII abundance or function. Supplementing rFVIII does not correct the underlying platelet-vWF hyperadhesion and will not prevent large-multimer depletion. Standard treatment is platelet transfusion; DDAVP is avoided because it releases endogenous vWF and can worsen thrombocytopenia. This prediction is most likely a network-proximity artefact rather than a genuine therapeutic opportunity. Across all 10 ranked predictions in this pack, the mechanistic links range from very weak to contraindicated (notably TTP at rank 10, where a pro-coagulant agent could be harmful).
Clinical Trial Evidence
Currently no related clinical trials registered for any of the 10 predicted indications.
Literature Evidence
Currently no related literature available for any of the 10 predicted indications.
All Predicted Indications — Mechanistic Assessment
Since this report covers a purely model-driven prediction set with no clinical evidence for any indication, a comparative mechanistic overview of all 10 ranked predictions is provided below to support the Hold decision:
| Rank | Disease | TxGNN Score | Mechanistic Assessment | Risk Flag |
|---|---|---|---|---|
| 1 | Pseudo-von Willebrand disease | 99.85% | Indirect: FVIII depletion is secondary to GPIb defect; rFVIII does not correct root cause | Network artefact |
| 2 | Primary release disorder of platelets | 99.84% | No link: dense/alpha-granule defects are in primary haemostasis; FVIII acts in secondary coagulation | No mechanistic basis |
| 3 | Glanzmann thrombasthenia | 99.76% | Weak: GPIIb/IIIa deficiency reduces platelet aggregation; rFVIII (unlike rFVIIa) requires functional platelet phospholipid surface to act | Should not be confused with rFVIIa indication |
| 4 | Scott syndrome | 99.44% | Theoretically partial: Scott syndrome impairs PS externalisation, which is the very scaffold FVIII needs — adding substrate without the scaffold has limited benefit | Theoretical substrate without scaffold |
| 5 | Acquired coagulation factor deficiency | 98.85% | Highest potential (if = Acquired Hemophilia A), but inhibitory antibodies limit standard rFVIII utility; obizur preferred | Highest of 10; still L5 |
| 6 | Bleeding diathesis due to collagen receptor defect | 98.71% | No link: GPVI/GP Ia-IIa defects are in platelet adhesion signalling, unrelated to FVIII | No mechanistic basis |
| 7 | Haemorrhagic disorder due to constitutional thrombocytopenia | 98.64% | Very weak: "coagulation support" concept unvalidated for rFVIII in thrombocytopenia | No clinical data |
| 8 | Oesophageal varices without bleeding | 98.41% | No link: portal hypertension treated by pressure reduction, not haemostatic augmentation; FVIII is typically normal/elevated in cirrhosis | No mechanistic basis |
| 9 | Oesophageal varices with bleeding | 98.41% | No link: multi-factor coagulation deficiency in liver disease; single FVIII supplementation insufficient | No mechanistic basis |
| 10 | Thrombotic thrombocytopenic purpura | 98.13% | Contraindicated direction: TTP is a thrombotic (not haemorrhagic) condition; adding rFVIII to a prothrombotic state could be harmful | ⚠️ High-risk false positive |
Singapore Market Information
Lonoctocog alfa is not registered in Singapore. There are no product authorisations on record.
Safety Considerations
Please refer to the package insert for safety information. No Singapore-registered package insert is available; consult the EMA/FDA prescribing information for AFSTYLA (CSL Behring).
Conclusion and Next Steps
Decision: Hold
Rationale: All 10 TxGNN-predicted indications currently sit at Evidence Level L5 (model prediction only, no clinical or preclinical studies identified), and mechanistic analysis indicates that the majority of predictions are likely knowledge-graph network-proximity artefacts arising from the tight vWF–FVIII coupling in the graph, rather than genuine drug-repurposing opportunities. One prediction (Acquired Coagulation Factor Deficiency, rank 5, if specifically referring to Acquired Hemophilia A) merits separate targeted investigation, but remains L5 pending any supporting data.
To proceed, the following is needed:
- Clarify the highest-potential indication: Determine whether rank 5 ("acquired coagulation factor deficiency") specifically refers to Acquired Hemophilia A (AHA); if so, commission a focused literature review on rFVIII utility in AHA versus inhibitor bypass strategies
- Retrieve full MOA data: Query DrugBank API for DB13998 to obtain complete pharmacodynamic, pharmacokinetic, and binding-site data (Data Gap DG002)
- Obtain Singapore/international prescribing information: Download and parse the FDA/EMA AFSTYLA label for contraindications, warnings, and populations (Data Gap DG001)
- Re-evaluate rank 3 (Glanzmann) separately: Although rFVIII is not indicated, rFVIIa is — this distinction should be documented to avoid clinical misinterpretation
- Flag rank 10 (TTP) as a confirmed false positive: Add to KG exclusion list to prevent this association from re-surfacing in future pipeline runs
- Do not pursue ranks 1, 2, 6, 8, 9 further: Mechanistic disconnection is fundamental, not a gap in evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.